US2007107076A1PendingUtilityA1
Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
Est. expiryJul 29, 2019(expired)· nominal 20-yr term from priority
C12N 15/8509C07K 14/82A01K 67/0271A01K 67/0276C12N 2840/203A01K 2217/05A01K 2227/105A01K 2217/075C07K 14/4738C12N 2517/02A01K 2267/0331C12N 2830/008A01K 2217/20C12N 2830/003A01K 67/0275
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A non-human mammal having incorporated into its genome an expression construct in which nucleic acid encoding and oncogene is operably linked to an inducible promoter; the mammal further has a genetic mutation that causes it to have an increased susceptibility to cancer.
Claims
exact text as granted — not AI-modified1 . A non-human mammal having incorporated into its genome an expression construct comprising nucleic acid encoding an oncogene operably linked to an inducible promoter, said mouse further comprising a genetic mutation that causes said mammal to have greater susceptibility to cancer than a mammal not comprising said mutation.
2 . The mammal of claim 1 , wherein said mammal is a mouse.
3 . The mammal of claim 1 , wherein said oncogene is ras.
4 . The mammal of claim 3 , wherein said ras has an activating mutation.
5 . The mammal of claim 1 , wherein said inducible promoter can be induced by doxycycline.
6 . The mammal of claim 1 , wherein said mutation is in DNA encoding a tumor suppressor.
7 . The mammal of claim 6 , wherein said tumor suppressor is INK4.
8 . A non-human mammal having incorporated into its genome: (i) a first expression construct comprising a reverse tetracycline transactivator operably linked to a tissue-specific promoter; and (ii) a second expression construct comprising nucleic acid encoding an oncogene operably linked to a promoter that can be regulated by said reverse tetracycline transactivator, said mammal further comprising a genetic mutation that causes said mammal to have greater susceptibility to cancer than a mammal not comprising said mutation.
9 . The mammal of claim 8 , wherein said tissue-specific promoter is a tyrosinase promoter.
10 . The mammal of claim 8 , wherein expression of said oncogene results in said mammal having greater susceptibility to cancer than a mammal comprising said mutation but not expressing said oncogene.
11 . A non-human mammal having incorporated into its genome: (i) a first expression construct comprising a reverse tetracycline transactivator operably linked to a tyrosinase promoter; and (ii) a second expression construct comprising nucleic acid encoding ras operably linked to a promoter that can be regulated by said reverse tetracycline transactivator.Join the waitlist — get patent alerts
Track US2007107076A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.